Evidence map›Paper›PMID 30941724›Full record

ArticleAdvances in therapy2019

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization.

Bing Ho, Hardik Bhagat, Jason J Schwartz, Kofi Atiemo, Amna Daud, Raymond Kang, Samantha E Montag, Lihui Zhao, Edward Lee, Anton I Skaro and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bing HoNorthwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA.
Hardik BhagatMedical Affairs, Americas, Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
Jason J SchwartzMedical Affairs, Americas, Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
Kofi AtiemoNorthwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA.
Amna DaudNorthwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA.
Raymond KangNorthwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA.
Samantha E MontagNorthwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA.
Lihui ZhaoNorthwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA.
Edward LeeMedical Affairs, Americas, Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.
Anton I SkaroDepartment of Surgery, Schulich School of Medicine and Dentistry, Western University, St. Joseph's Hospital, 268 Grosvenor Street, Rm. E3-117, London, ON, N6A 4V2, Canada.
Daniela P LadnerNorthwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center, Northwestern University, 676 N. St. Clair Street, 19th Floor, Chicago, IL, 60611, USA. dladner@nm.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionReal-world data with extended-release tacrolimus (ER-T) are lacking in the USA. This study examined clinical outcomes and healthcare resource utilization in kidney transplant patients receiving ER-T in clinical practice.

methodsThis was a retrospective, single-center analysis (February-June 2016) using data from Northwestern University's Enterprise Data Warehouse. Adult patients receiving a kidney transplant in the preceding 4 years, treated de novo or converted to ER-T from immediate-release tacrolimus (IR-T) within 10 days post-transplantation, and maintained on ER-T (at least 3 months) were included. Patients were matched for demographic and clinical characteristics with IR-T-treated control patients. Endpoints included clinical outcomes and healthcare resource utilization up to 1 year post-transplantation.

resultsA total of 19 ER-T-treated patients were matched with 55 IR-T-treated patients. No ER-T-treated patients experienced biopsy-confirmed acute rejection (BCAR) or graft failure versus 3 (5.5%) and 3 (5.5%) IR-T-treated patients, respectively. Mean estimated glomerular filtration rate (eGFR), the number of all-cause outpatient visits, readmissions, and all-cause hospitalization days were comparable between groups. Tacrolimus trough levels, days to target level (6-10 ng/mL), and number of required dose adjustments were also similar.

conclusionReal-world clinical outcomes and healthcare resource utilization were similar with ER-T and IR-T. Larger studies will need to investigate the trend toward fewer BCAR events, and increased graft survival with ER-T.

fundingAstellas Pharma Global Development, Inc. Plain language summary available for this article.

Indexed as

AdultAgedCalcineurin InhibitorsDelayed-Action PreparationsDrug Administration ScheduleFemaleGraft RejectionHumansImmunosuppressive AgentsKidney TransplantationMaleMiddle AgedRetrospective StudiesTacrolimusUnited StatesYoung AdultCalcineurin InhibitorsDelayed-Action PreparationsImmunosuppressive AgentsTacrolimusCalcineurin inhibitorGlomerular filtration rate (GFR)Graft survivalImmunosuppressantKidney (allograft) function/dysfunctionPatient characteristicsTacrolimusUrology

Identifiers

PMID30941724
PMCPMC6824361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.